Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling
المؤلفون المشاركون
Dean, Andrew
Byrne, Aisling
Marinova, Mira
Hayden, Ingrid
المصدر
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-07-21
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Patients with heavily pretreated advanced cancer or with rare tumors are difficult to treat.
Molecular profiling (MP) of tumors to identify biomarkers that predict potential outcomes with individual therapies is an emerging strategy to guide treatment decisions.
Patients with rare tumors for which standard-of-care therapy was unavailable or more common tumors for which standard-of-care options had been exhausted underwent MP at a single Australian center.
Data regarding treating physicians’ choice of therapy, MP results and recommendations, and patient outcomes were collected.
Seven patients had received prior standard first-line therapy (PST), 16 had rare tumors, and 31 had been heavily pretreated (HPT; ≥2 prior lines).
Most treatments suggested by MP (541/594; 91.1%) were common chemotherapy drugs available in generic formulations.
MP-guided therapy recommendations differed from physician’s recommendations in 48 patients (88.9%).
MP-guided therapy produced clinical benefit (improved QOL and/or performance status, symptoms, bodyweight, or RECIST) in 19/31 (61.3%), 11/16 (68.8%), and 3/7 (42.9%) patients with HPTs, rare tumors, and PSTs, respectively, and had a PFS ratio ≥1.3 in 22/37 evaluable patients (59.5%; 95% confidence interval 44–76%).
The null hypothesis that ≤15% of these patients would have a PFS ratio ≥1.3 was rejected (one-sided p < 0.0001 ).
In conclusion, using MP to guide therapy selection is feasible in clinical practice and may improve patient outcomes.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Dean, Andrew& Byrne, Aisling& Marinova, Mira& Hayden, Ingrid. 2016. Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. BioMed Research International،Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1097828
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Dean, Andrew…[et al.]. Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. BioMed Research International No. 2016 (2016), pp.1-9.
https://search.emarefa.net/detail/BIM-1097828
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Dean, Andrew& Byrne, Aisling& Marinova, Mira& Hayden, Ingrid. Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling. BioMed Research International. 2016. Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1097828
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1097828
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر